Trends in Complications and Outcomes in Patients Aged 65 Years and Younger Undergoing Total Knee Arthroplasty: Data From the American Joint Replacement Registry

医学 生存曲线 共病 查尔森共病指数 关节置换术 外科 单变量分析 回顾性队列研究 人口
作者
Akash Shah,David Alexander Cieremans,James Slover,Ran Schwarzkopf,Morteza Meftah
出处
期刊:Journal of the American Academy of Orthopaedic Surgeons [Wolters Kluwer]
卷期号:6 (6)
标识
DOI:10.5435/jaaosglobal-d-22-00116
摘要

The purpose of this study was to identify common complications and the rates of readmission and revision in total knee arthroplasty (TKA) patients younger than 65 years.Using the American Joint Replacement Registry, we conducted a retrospective review of all TKAs done in patients aged 18 to 65 years from 2012 to 2020. Demographic factors such as age, sex, Charlson Comorbidity Index (CCI), and preoperative Veterans RAND 12-Item Health Survey Physical Component Summary (VR-12 PCS) scores were collected. We excluded patients older than 65 years and revision, oncologic, and nonelective cases. Primary outcomes included cumulative revision rate, 90-day readmission rate, and reason for revision. Univariate analysis and the Kaplan-Meier method were used.Six thousand one hundred seventy-nine patients were included. The average age was 58.8 years (SD 5.5 years), 61% were female, 82% were White, and 88% had a CCI of 0 (1 = 8% and ≥2 = 4%). The mean follow-up was 42.51 months. Seventy-four patients (1.2%) underwent revision. Sixty-nine patients (1.1%) were readmitted within 90 days. No factors assessed increased revision rates. Revision-free survivorship was 98.7% (95% CI 98.4 to 99.0) and 98.6% (95% CI 98.2 to 99.0) at 5 and 8 years, respectively. Infection (15%), aseptic loosening (14%), and instability (12%) were the most common indications for revision.TKA done in young and presumed active patients has excellent survivorship. Long-term follow-up is needed to assess survival trends in this growing population.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.3应助若梦易燃采纳,获得10
刚刚
科研通AI6.1应助若梦易燃采纳,获得10
刚刚
刚刚
科研通AI6.2应助若梦易燃采纳,获得10
刚刚
刚刚
科研通AI6.3应助若梦易燃采纳,获得10
刚刚
李健应助jed采纳,获得10
刚刚
张欣鹏完成签到,获得积分10
刚刚
Garcia应助逐风采纳,获得10
刚刚
科研通AI6.1应助若梦易燃采纳,获得100
刚刚
研友_VZG7GZ应助若梦易燃采纳,获得30
刚刚
星辰大海应助若梦易燃采纳,获得100
刚刚
科研通AI6.3应助若梦易燃采纳,获得200
1秒前
科研通AI6.1应助若梦易燃采纳,获得100
1秒前
LLK完成签到,获得积分10
1秒前
1秒前
Weirdo完成签到,获得积分10
1秒前
1秒前
情怀应助hbzjt2012采纳,获得10
1秒前
2秒前
量子星尘发布了新的文献求助10
2秒前
2秒前
2秒前
Ava应助Yue采纳,获得10
2秒前
2秒前
3秒前
3秒前
Sheya发布了新的文献求助10
3秒前
苏兜兜完成签到,获得积分10
3秒前
传奇3应助飘逸秋双采纳,获得10
3秒前
4秒前
柒玖发布了新的文献求助10
4秒前
丘比特应助轻松的芯采纳,获得10
4秒前
杨修发布了新的文献求助10
4秒前
阿凡发布了新的文献求助10
4秒前
聆春愿发布了新的文献求助10
4秒前
领导范儿应助斯文的含烟采纳,获得10
5秒前
淳于语海发布了新的文献求助10
5秒前
lyy发布了新的文献求助10
5秒前
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of pharmaceutical excipients, Ninth edition 5000
Aerospace Standards Index - 2026 ASIN2026 3000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
Principles of town planning : translating concepts to applications 500
Short-Wavelength Infrared Windows for Biomedical Applications 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6060287
求助须知:如何正确求助?哪些是违规求助? 7892761
关于积分的说明 16302721
捐赠科研通 5204362
什么是DOI,文献DOI怎么找? 2784323
邀请新用户注册赠送积分活动 1766998
关于科研通互助平台的介绍 1647287